Insider transactions

EDGAR

BioNexus Gene Lab Corp.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–5 of 5

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-08-13 Filed 2026-08-14Bin Abdul Hamid Muhammad Azrul Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Shares
Acquired (A)32,258——32,258Direct (D) No
F1
  • F1 Represents a fully vested Other Stock-Based Award of 32,258 shares of common stock, no par value, granted on August 13, 2026 under the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan. The award was granted for completed services, for no cash consideration and valued for Plan purposes at $1.55 per share (the Nasdaq closing price on August 12, 2026).
Open filing 0001520138-26-000347 Read from the filing’s XML Dispute this row
2026-08-13 Filed 2026-08-14Chong Set Fui Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Shares
Acquired (A)96,774——96,774Direct (D) No
F1
  • F1 Represents a fully vested Other Stock-Based Award of 96,774 shares of common stock, no par value, granted on August 13, 2026 under the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan. The award was granted for completed services, for no cash consideration and valued for Plan purposes at $1.55 per share (the Nasdaq closing price on August 12, 2026).
Open filing 0001520138-26-000346 Read from the filing’s XML Dispute this row
2026-08-13 Filed 2026-08-14Tan Lee Su-Leng Director · Officer: Chief Executive Officer · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Shares
Acquired (A)338,709——338,709Direct (D) No
F1
  • F1 Represents a fully vested Other Stock-Based Award of 338,709 shares of common stock, no par value, granted on August 13, 2026 under the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan. The award was granted for completed services, for no cash consideration and valued for Plan purposes at $1.55 per share (the Nasdaq closing price on August 12, 2026).
Open filing 0001520138-26-000349 Read from the filing’s XML Dispute this row
2026-08-13 Filed 2026-08-14Yap Chee Keong Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Shares
Acquired (A)32,258——32,258Direct (D) No
F1
  • F1 Represents a fully vested Other Stock-Based Award of 32,258 shares of common stock, no par value, granted on August 13, 2026 under the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan. The award was granted for completed services, for no cash consideration and valued for Plan purposes at $1.55 per share (the Nasdaq closing price on August 12, 2026).
Open filing 0001520138-26-000348 Read from the filing’s XML Dispute this row
2026-08-13 Filed 2026-08-14Low Jook Yuen Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)16,129——17,390Direct (D) No
F1
  • F1 Represents a fully vested Other Stock-Based Award of 16,129 shares of common stock, no par value, granted on August 13, 2026 under the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan. The award was granted for completed services, for no cash consideration and valued for Plan purposes at $1.55 per share (the Nasdaq closing price on August 12, 2026).
Open filing 0001520138-26-000345 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.

Showing 1–4 of 4

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
UBS Group AG Partly reported under another manager306 SH373 dollarsHigher by 205 Prior quarter: 101Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
Caitong International Asset Management Co., Ltd 137 SH167 dollarsHigher by 136 Prior quarter: 1Open filing 0001628280-26-068135 Filed 2026-10-29 Dispute this row
Tower Research Capital LLC (TRC) Partly reported under another manager12 SH15 dollarsNot in the prior quarter’s filings read Open filing 0001533421-26-000010 Filed 2026-11-16 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager2 SH3 dollarsNot in the prior quarter’s filings read Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • HRT FINANCIAL LP 14,283 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Tan Lee Su-Leng Common Stock, no par value11.5338,709.0008/13/2026 Filed 2026-08-14SCHEDULE 13DOpen filing 0001520138-26-000354 Dispute this row
Fidelion Diagnostics Pte. Ltd. COMMON STOCK, NO PAR VALUE13.4392,329.0011/28/2025 Filed 2026-10-22SCHEDULE 13GOpen filing 0001520138-26-000439 Dispute this row
MOLECULE BIO LLC COMMON STOCK, NO PAR VALUE13.4392,329.0011/28/2025 Filed 2026-10-22SCHEDULE 13GOpen filing 0001520138-26-000439 Dispute this row
XIAO LING COMMON STOCK, NO PAR VALUE13.4392,329.0011/28/2025 Filed 2026-10-22SCHEDULE 13GOpen filing 0001520138-26-000439 Dispute this row
RAINY MORNING TECHNOLOGY (HONG KONG) LIMITED COMMON STOCK, NO PAR VALUE13.4392,329.0011/28/2025 Filed 2026-10-22SCHEDULE 13GOpen filing 0001520138-26-000439 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,715,586 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015131,968
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,828

Filings made before the SEC required XML are listed, not extracted.

Back to BioNexus Gene Lab Corp.